Smt Kanuri Santhamma Center for Vitreoretinal Diseases, Anant Bajaj Retina Institute, L. V. Prasad Eye Institute, Hyderabad, India.
Department of Ophthalmology, Doheny Eye Institute, Los Angeles, California.
Ocul Immunol Inflamm. 2024 Jul;32(5):525-528. doi: 10.1080/09273948.2024.2316754. Epub 2024 Feb 26.
Intravitreal Ganciclovir has been one of the treatments of choice for cytomegalovirus (CMV) retinitis and has been used extensively for its treatment since 1987. It has not been shown to have any major adverse effects. There are no reports on any retinal toxicity even after multiple, repeated injections. Herein, we report a rare case of retinal toxicity after multiple intravitreal injections in a patient of CMV retinitis.
A 69-year-old one eyed male, who was on oral corticosteroids and systemic immunosuppression for Granulomatosis with Polyangiitis, presented with CMV retinitis in both eyes. His visual acuity was 20/60 in his right eye and no perception of light in his left eye. He was treated with multiple injections of intravitreal Ganciclovir in his right eye. The left eye was not treated since it had no vision potential. The right eye of the patient which had received multiple injections went on to developed a progressive diffuse atrophy of Retinal Pigment Epithelium (RPE). No such changes were noted in the left eye of the patient.
We present a case of progressive diffuse RPE atrophy as a result of toxicity of intravitreal ganciclovir injections. It is important to be aware of this rare potential toxicity of intravitreal Ganciclovir.
眼内注射更昔洛韦一直是巨细胞病毒(CMV)视网膜炎的治疗选择之一,自 1987 年以来,因其治疗效果广泛应用于临床。它没有显示出任何重大的不良反应。即使多次重复注射,也没有关于任何视网膜毒性的报告。在此,我们报告一例 CMV 视网膜炎患者多次眼内注射后罕见的视网膜毒性病例。
一名 69 岁男性,因血管炎伴肉芽肿病正在接受口服皮质类固醇和全身免疫抑制治疗,双眼患有 CMV 视网膜炎。他右眼视力为 20/60,左眼无光感。他右眼接受了多次眼内注射更昔洛韦治疗。左眼由于没有视力潜力,未进行治疗。接受多次注射的右眼逐渐出现弥漫性视网膜色素上皮(RPE)进行性萎缩。患者左眼未见这种变化。
我们提出了一例眼内注射更昔洛韦引起的进行性弥漫性 RPE 萎缩的病例。了解这种眼内注射更昔洛韦的罕见潜在毒性非常重要。